{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:24:12Z","timestamp":1792517052269,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cystic fibrosis is a serious life-threatening hereditary disease that occurs due to a mutation in the cystic fibrosis transmembrane conductance regulator gene (<jats:italic>CFTR<\/jats:italic>). Ivacaftor (IVA) is a drug that targets the mutated CFTR protein. IVA is highly hydrophobic (log <jats:italic>P<\/jats:italic>\u2009=\u20095.6) with poor aqueous solubility (0.05 \u00b5g\/mL) and is formulated as an amorphous solid dispersion tablet under the brand name Kalydeco<jats:sup>\u00ae<\/jats:sup>. The recommended daily dose of Kalydeco<jats:sup>\u00ae<\/jats:sup> is twice per day with a high fat meal to aid in IVA\u2019s absorption. In this research, we studied the application of cyclodextrins (CDs) to improve the dissolution of IVA. Phase solubility studies between IVA and four different CDs (\u03b1-, \u03b2-, \u03b3-, and hydroxypropyl-\u03b2-CD [HP-\u03b2-CD]) were conducted and\u00a0a significant improvement in IVA\u2019s aqueous solubility with HP-\u03b2-CD\u00a0was observed. Solid state characterizations confirmed the formation of IVA\/HP-\u03b2-CD inclusion complexes. <jats:italic>In vitro<\/jats:italic> dissolution studies were conducted at pH\u2009=\u20096.8 and showed improvement in IVA\u2019s rate and extent of dissolution with IVA\/HP-\u03b2-CD (1:2) complexes in comparison to uncomplexed IVA. <jats:italic>In vivo<\/jats:italic> pharmacokinetics in mice showed a\u00a02-fold increase in area under the curve (AUC) after the oral administration of the\u00a0IVA\/HP-\u03b2-CD complex in comparison to Kalydeco tablets. In addition, HP-\u03b2-CD extended the release of IVA from the IVA\/HP-\u03b2-CD complexes with a longer T<jats:sub>max<\/jats:sub> of 7.05 h compared to 2.96 h with Kalydeco<jats:sup>\u00ae<\/jats:sup> tablets. These results demonstrate that CD inclusion complexes of IVA using HP-\u03b2-CD can be a successful alternative approach to improving the solubility of IVA while extending its release.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12249-025-03131-6","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T21:01:41Z","timestamp":1747429301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cyclodextrin-Based Inclusion Complexes Improve the In Vitro Solubility and Pharmacokinetics of Ivacaftor Following Oral Administration in Mice"],"prefix":"10.1208","volume":"26","author":[{"given":"David S.","family":"Nakhla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef W.","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walla","family":"Malkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Acri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-6633","authenticated-orcid":false,"given":"Aliasger K.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"3131_CR1","doi-asserted-by":"publisher","unstructured":"Ikpa PT, Bijvelds MJC, De Jonge HR. Cystic fibrosis: Toward personalized therapies. International Journal of Biochemistry and Cell Biology. 2014;52:192\u2013200. Available from: https:\/\/doi.org\/10.1016\/j.biocel.2014.02.008.","DOI":"10.1016\/j.biocel.2014.02.008"},{"issue":"1","key":"3131_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5863\/1551-6776-18.1.8","volume":"18","author":"ME Condren","year":"2013","unstructured":"Condren ME, Bradshaw MD. Ivacaftor: A Novel Gene-Based Therapeutic Approach for Cystic Fibrosis. The Journal of Pediatric Pharmacology and Therapeutics. 2013;18(1):8\u201313.","journal-title":"The Journal of Pediatric Pharmacology and Therapeutics"},{"issue":"12","key":"3131_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Lumacaftor\/Ivacaftor: A Review in Cystic Fibrosis. Drugs. 2016;76(12):1191\u2013201.","journal-title":"Drugs"},{"issue":"18","key":"3131_CR4","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Elexacaftor\/Ivacaftor\/Tezacaftor: First Approval. Drugs. 2019;79(18):2001\u20137. https:\/\/doi.org\/10.1007\/s40265-019-01233-7.","journal-title":"Drugs."},{"issue":"1","key":"3131_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/FPC.0000000000000246","volume":"27","author":"AE Fohner","year":"2017","unstructured":"Fohner AE, McDonagh EM, Clancy JP, Whirl Carrillo M, Altman RB, Klein TE. PharmGKB summary: Ivacaftor pathway, pharmacokinetics\/pharmacodynamics. Pharmacogenet Genomics. 2017;27(1):39\u201342.","journal-title":"Pharmacogenet Genomics"},{"key":"3131_CR6","unstructured":"Kalydeco (Ivacaftor) [package insert]. U.S. Food and Drug Administration. 2012."},{"key":"3131_CR7","unstructured":"National Institute of Health (NIH); National Library of Medicine (NLM): Ivacaftor, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ivacaftor."},{"key":"3131_CR8","doi-asserted-by":"crossref","unstructured":"Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. Vol. 26, Oman Medical Specialty Board Oman Medical Journal. 2011.","DOI":"10.5001\/omj.2011.38"},{"issue":"7","key":"3131_CR9","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1097\/j.pain.0000000000002841","volume":"164","author":"JB Lesnak","year":"2022","unstructured":"Lesnak JB, Nakhla DS, Plumb AN, McMillan A, Saha S, Gupta N, et al. Selective androgen receptor modulator microparticle formulation reverses muscle hyperalgesiain a mouse model of widespread muscle pain. Pain. 2022;164(7):1512\u201323.","journal-title":"Pain."},{"issue":"5","key":"3131_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jcf.2015.05.009","volume":"14","author":"CM Siracusa","year":"2015","unstructured":"Siracusa CM, Ryan J, Burns L, Wang Y, Zhang N, Clancy JP, et al. Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. J Cyst Fibros. 2015;14(5):621\u20136.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"3131_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jcf.2006.03.002","volume":"5","author":"AC Modi","year":"2006","unstructured":"Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006;5(3):177\u201385.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3131_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/thx.51.1.29","volume":"51","author":"SP Conway","year":"1996","unstructured":"Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax. 1996;51(1):29\u201333.","journal-title":"Thorax"},{"key":"3131_CR13","doi-asserted-by":"crossref","unstructured":"Hedges A. Chapter 22 - Cyclodextrins: Properties and applications, in food science and technology, starch (third edition). In: BeMiller J, Whistler R,\u00a0editors. Academic Press; 2009. pp. 833\u201351.","DOI":"10.1016\/B978-0-12-746275-2.00022-7"},{"key":"3131_CR14","doi-asserted-by":"crossref","unstructured":"Loftsson T, Brewster ME, Park H, Otte A, Park K, National Osteoporosis Foundation, et al. Pharmaceutical applications of cyclodextrins: Basic science and product development. Journal of Controlled Release. 2010;342(December 2021):1607\u201321. Available from: www.nof.org.","DOI":"10.1111\/j.2042-7158.2010.01030.x"},{"key":"3131_CR15","doi-asserted-by":"crossref","unstructured":"Naguib YW, Saha S, Skeie JM, Ebeid K, Abdel-rahman S, Kesh S, et al. Solubilized Ubiquinol for Preserving Corneal Function. 2021. Available from: https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/.","DOI":"10.1016\/j.biomaterials.2021.120842"},{"key":"3131_CR16","first-page":"650","volume":"25","author":"DS Nakhla","year":"2024","unstructured":"Nakhla DS, Mekkawy AI, Naguib YW, Silva AD, Gao D, Ah Kim J, et al. Injectable long-acting ivacaftor-loaded poly (lactide-co-glycolide) microparticle formulations for the treatment of cystic fibrosis: In vitro characterization and in vivo pharmacokinetics in mice. Int J Pharm. 2024;25:650.","journal-title":"Int J Pharm"},{"issue":"2","key":"3131_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455\u201361.","journal-title":"J Comput Chem"},{"issue":"16","key":"3131_CR18","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Ruth H, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785\u201391.","journal-title":"J Comput Chem"},{"key":"3131_CR19","unstructured":"Higuchi, T. C, K.A. Phase solubility techniques. Advances in Analytical Chemistry Instrumentation, fourth ed. Wiley-Interscience, New York. 1965."},{"key":"3131_CR20","doi-asserted-by":"crossref","unstructured":"Lima B dos S, Campos C de A, da Silva Santos ACR, Santos VCN, Trindade G das GG, Shanmugam S, et al. Development of morin\/hydroxypropyl-\u03b2-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects. Food and Chemical Toxicology. 2019;126(February):15\u201324.","DOI":"10.1016\/j.fct.2019.01.038"},{"issue":"5","key":"3131_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ddr.21452","volume":"79","author":"S Jacob","year":"2018","unstructured":"Jacob S, Nair AB. Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev Res. 2018;79(5):201\u201317.","journal-title":"Drug Dev Res"},{"issue":"1","key":"3131_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41565-017-0009-7","volume":"13","author":"K Ebeid","year":"2018","unstructured":"Ebeid K, Meng X, Thiel KW, Do AV, Geary SM, Morris AS, et al. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol. 2018;13(1):72\u201381.","journal-title":"Nat Nanotechnol"},{"key":"3131_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.actbio.2017.01.005","volume":"50","author":"EI Wafa","year":"2017","unstructured":"Wafa EI, Geary SM, Goodman JT, Narasimhan B, Salem AK. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response. Acta Biomater. 2017;50:417\u201327.","journal-title":"Acta Biomater"},{"issue":"10","key":"3131_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11095-019-2681-9","volume":"36","author":"BA Young","year":"2019","unstructured":"Young BA, Bahl D, Stevens LL. Understanding the tabletability differences between indomethacin polymorphs using powder brillouin light scattering. Pharm Res. 2019;36(10):150.","journal-title":"Pharm Res."},{"key":"3131_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopha.2017.06.091","volume":"93","author":"YMBG Carvalho","year":"2017","unstructured":"Carvalho YMBG, Menezes PP, Sousa BMH, Lima BS, Trindade IAS, Serafini MR, et al. Inclusion complex between \u03b2-cyclodextrin and hecogenin acetate produces superior analgesic effect in animal models for orofacial pain. Biomed Pharmacother. 2017;93:754\u201362.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3131_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/1570163812666150109103618","volume":"11","author":"A Sherje","year":"2015","unstructured":"Sherje A, Londhe V. Inclusion Complexes of Hydroxy Propyl-\u03b2-Cyclodextrin and Paliperidone: Preparation and Characterization. Curr Drug Discov Technol. 2015;11(4):271\u20138.","journal-title":"Curr Drug Discov Technol"},{"key":"3131_CR27","doi-asserted-by":"publisher","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306\u201314. Available from: https:\/\/doi.org\/10.1016\/j.cmpb.2010.01.007.","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"3131_CR28","doi-asserted-by":"crossref","unstructured":"Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug\/cyclodextrin complexes. Vol. 23, Molecules. MDPI AG; 2018.","DOI":"10.3390\/molecules23051161"},{"key":"3131_CR29","doi-asserted-by":"crossref","unstructured":"Lima B dos S, Campos C de A, da Silva Santos ACR, Santos VCN, Trindade G das GG, Shanmugam S, et al. Development of morin\/hydroxypropyl-\u03b2-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects. Food and Chemical Toxicology. 2019;126(January):15\u201324.","DOI":"10.1016\/j.fct.2019.01.038"},{"key":"3131_CR30","doi-asserted-by":"publisher","unstructured":"Wang L, Yan J, Li Y, Xu K, Li S, Tang P, et al. The influence of hydroxypropyl-\u03b2-cyclodextrin on the solubility, dissolution, cytotoxicity, and binding of riluzole with human serum albumin. J Pharm Biomed Anal. 2016;117:453\u201363. Available from: https:\/\/doi.org\/10.1016\/j.jpba.2015.09.033.","DOI":"10.1016\/j.jpba.2015.09.033"},{"key":"3131_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.carbpol.2014.04.006","volume":"110","author":"Y Yao","year":"2014","unstructured":"Yao Y, Xie Y, Hong C, Li G, Shen H, Ji G. Development of a myricetin\/hydroxypropyl-\u03b2-cyclodextrin inclusion complex: Preparation, characterization, and evaluation. Carbohydr Polym. 2014;110:329\u201337.","journal-title":"Carbohydr Polym"},{"key":"3131_CR32","doi-asserted-by":"publisher","unstructured":"Wang L, Li S, Tang P, Yan J, Xu K, Li H. Characterization and evaluation of synthetic riluzole with \u03b2-cyclodextrin and 2,6-di-O-methyl-\u03b2-cyclodextrin inclusion complexes. Carbohydr Polym. 2015;129:9\u201316. Available from: https:\/\/doi.org\/10.1016\/j.carbpol.2015.04.046.","DOI":"10.1016\/j.carbpol.2015.04.046"},{"key":"3131_CR33","doi-asserted-by":"publisher","unstructured":"Hu L, Zhang H, Song W, Gu D, Hu Q. Investigation of inclusion complex of cilnidipine with hydroxypropyl- \u03b2-cyclodextrin. Carbohydr Polym. 2012;90(4):1719\u201324. Available from: https:\/\/doi.org\/10.1016\/j.carbpol.2012.07.057.","DOI":"10.1016\/j.carbpol.2012.07.057"},{"issue":"3","key":"3131_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.carbpol.2010.09.007","volume":"83","author":"J Zeng","year":"2011","unstructured":"Zeng J, Ren Y, Zhou C, Yu S, Chen WH. Preparation and physicochemical characteristics of the complex of edaravone with hydroxypropyl-\u03b2-cyclodextrin. Carbohydr Polym. 2011;83(3):1101\u20135.","journal-title":"Carbohydr Polym"},{"key":"3131_CR35","unstructured":"Thaimattam R, Dama VSR, Indukuri V, Kumar S, Gorantla SRA, Chava S. Novel Polymorphs of ivacaftot, process for its preparation and pharmaceutical composition thereof. US Patent.\u00a0US20170334860A1.\u00a02016."},{"key":"3131_CR36","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.msec.2017.03.197","volume":"76","author":"LJ Yang","year":"2017","unstructured":"Yang LJ, Wang SH, Zhou SY, Zhao F, Chang Q, Li MY, et al. Supramolecular system of podophyllotoxin and hydroxypropyl-\u03b2-cyclodextrin: Characterization, inclusion mode, docking calculation, solubilization, stability and cytotoxic activity. Mater Sci Eng, C. 2017;76:1136\u201345.","journal-title":"Mater Sci Eng, C"},{"key":"3131_CR37","doi-asserted-by":"publisher","unstructured":"Yuvaraja K, Khanam J. Enhancement of carvedilol solubility by solid dispersion technique using cyclodextrins, water soluble polymers and hydroxyl acid. J Pharm Biomed Anal. 2014;96:10\u201320. Available from: https:\/\/doi.org\/10.1016\/j.jpba.2014.03.019.","DOI":"10.1016\/j.jpba.2014.03.019"},{"issue":"1","key":"3131_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jpba.2005.06.022","volume":"40","author":"L Liu","year":"2006","unstructured":"Liu L, Zhu S. Preparation and characterization of inclusion complexes of prazosin hydrochloride with \u03b2-cyclodextrin and hydroxypropyl-\u03b2-cyclodextrin. J Pharm Biomed Anal. 2006;40(1):122\u20137.","journal-title":"J Pharm Biomed Anal"},{"issue":"45","key":"3131_CR39","doi-asserted-by":"publisher","first-page":"26109","DOI":"10.1039\/C9RA04448E","volume":"9","author":"S Gao","year":"2019","unstructured":"Gao S, Bie C, Ji Q, Ling H, Li C, Fu Y, et al. Preparation and characterization of cyanazine-hydroxypropyl-beta-cyclodextrin inclusion complex. RSC Adv. 2019;9(45):26109\u201315.","journal-title":"RSC Adv"},{"key":"3131_CR40","doi-asserted-by":"publisher","unstructured":"Yang Y, Gao J, Ma X, Huang G. Inclusion complex of tamibarotene with hydroxypropyl-\u03b2-cyclodextrin: Preparation, characterization, in-vitro and in-vivo evaluation. Asian J Pharm Sci. 2017;12(2):187\u201392. Available from: https:\/\/doi.org\/10.1016\/j.ajps.2016.08.009.","DOI":"10.1016\/j.ajps.2016.08.009"},{"issue":"23\u201324","key":"3131_CR41","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","volume":"12","author":"T Vasconcelos","year":"2007","unstructured":"Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23\u201324):1068\u201375.","journal-title":"Drug Discov Today"},{"key":"3131_CR42","first-page":"189","volume":"1","author":"MM Tzanova","year":"2023","unstructured":"Tzanova MM, Nguyen L, Moretti F, Grassi M, Magnano GC, Voinovich D, et al. Interpreting permeability as a function of free drug fraction: The case studies of cyclodextrins and liposomes. Eur J Pharm Sci. 2023;1:189.","journal-title":"Eur J Pharm Sci"},{"issue":"178","key":"3131_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejpb.2022.08.009","volume":"1","author":"MM Tzanova","year":"2022","unstructured":"Tzanova MM, Moretti F, Grassi G, Stein PC, Hiorth M, Abrami M, et al. Modelling drug diffusion through unstirred water layers allows real-time quantification of free\/loaded drug fractions and release kinetics from colloidal-based formulations. Eur J Pharm Biopharm. 2022;1(178):168\u201378.","journal-title":"Eur J Pharm Biopharm"},{"key":"3131_CR44","doi-asserted-by":"crossref","unstructured":"Loftsson T, Vogensen SB, Brewster ME, Konr\u00e1osd\u00f3ttir F. Effects of cyclodextrins on drug delivery through biological membranes. Vol. 96, Journal of Pharmaceutical Sciences. John Wiley and Sons Inc.; 2007. p. 2532\u201346.","DOI":"10.1002\/jps.20992"},{"key":"3131_CR45","doi-asserted-by":"publisher","unstructured":"Tsai Shu-Pei Wu Eric Haseltine Sanjeev Kumar Samuel Moskowitz Paul Panorchan Kushal Shah AM. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor\/Tezacaftor\/Ivacaftor. Pulm Ther. 6. Available from: https:\/\/doi.org\/10.6084\/m9.figshare.12666467.","DOI":"10.6084\/m9.figshare.12666467"},{"key":"3131_CR46","unstructured":"Masson M, Loftsson Thorsteinn, Masson Gisli, Stefansson Einar. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing."},{"issue":"1","key":"3131_CR47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1271\/bbb.69.246","volume":"69","author":"M Ishikawa","year":"2005","unstructured":"Ishikawa M, Yoshii H, Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci Biotechnol Biochem. 2005;69(1):246\u20138.","journal-title":"Biosci Biotechnol Biochem"},{"key":"3131_CR48","doi-asserted-by":"crossref","unstructured":"Kato M. Intestinal First-Pass Metabolism of CYP3A4 Substrates. Vol. 23, Drug Metab. Pharmacokinet. 2008. Available from: http:\/\/www.jstage.jst.go.jp\/browse\/dmpk.","DOI":"10.2133\/dmpk.23.87"},{"key":"3131_CR49","doi-asserted-by":"crossref","unstructured":"Flourie B, Molis C, Achour L, Dupas H, Hatat C, Claude Rambaud J. Fate of beta-cyclodextrin in the human intestine. Vol. 123, J. Nutr. 1993.","DOI":"10.1093\/jn\/123.4.676"},{"key":"3131_CR50","doi-asserted-by":"crossref","unstructured":"Loftsson T, Brewster ME, M\u00e1sson M. Role of Cyclodextrins in Improving Oral Drug Delivery. Vol. 2, Am J Drug Deliv. 2004.","DOI":"10.2165\/00137696-200402040-00006"},{"key":"3131_CR51","doi-asserted-by":"crossref","unstructured":"Jacobsen AC, Visentin S, Butnarasu C, Stein PC, di Cagno MP. Commercially Available Cell-Free Permeability Tests for Industrial Drug Development: Increased Sustainability through Reduction of In Vivo Studies. Vol. 15, Pharmaceutics. MDPI; 2023.","DOI":"10.3390\/pharmaceutics15020592"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03131-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:46:12Z","timestamp":1751906772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03131-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3131"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03131-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work has resulted in a U.S. patent application for Compositions comprising molecules for cystic fibrosis treatment. Patent number: WO2022125963 A1 for Aliasger K. Salem, David A. Stoltz, Michael J. Welsh, Sarah Ernst, Youssef W. Naguib, David Nakhla, Aml I. Mekkawy, Nikesh Gupta.PCT\/US2021\/062913.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"135"}}